

A Support Vector Machine based Prediction Model for Discrimination of Malignant Pulmonary Nodules from Benign Nodules

Yan Wu^{1,2}, Emmanuel Zachariah¹, Judith K. Amorosa², Anjani Naidu², Mina L. Labib², Jamil Shaikh², Donna Eckstein², Sinae Kim³, John E. Langenfeld¹, Joseph Aisner¹, John L. Noshier², Robert S. DiPaola¹ and David J. Foran¹

¹Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey,
195 Little Albany Street, New Brunswick, NJ 08903, U.S.A.

²Department of Radiology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey,
1 Robert Wood Johnson Place, New Brunswick, NJ 08901, U.S.A.

³Department of Biostatistics, Rutgers School of Public Health, Rutgers, The State University of New Jersey,
683 Hoes Lane West, Piscataway, NJ 08854, U.S.A.

Keywords: Support Vector Machine, Malignant Nodules, Benign Nodules, Pulmonary Nodules, Prediction Model.

Abstract: Lung cancer is the leading cause of cancer death in the United States and worldwide. Most patients are diagnosed at an advanced stage, usually stage III or IV. Identification of lung cancer patients at an early stage might enable oncologists to surgically remove the tumors. Currently, low dose CT scans are used to identify the malignant nodules in high risk patients. However, screening CT scans yield a high rate of false-positive results. A prediction model was developed for improved discrimination of malignant nodules from benign nodules in patients who underwent lung screening CT. CT images and clinical outcomes of 39 patients were obtained from the National Lung Screening Trial (NLST), National Cancer Institute, National Institute of Health. Images were analyzed to extract computational features relevant to malignancy prediction. A Support Vector Machine (SVM) based model was developed to predict the malignancy of nodules. During pilot studies, our model achieved the following prediction performance: accuracy of 0.74, sensitivity of 0.85, and specificity of 0.61.

1 INTRODUCTION

Lung cancer is the leading cause of cancer death in the United States and worldwide. The mortality rate from lung cancer is greater than the number of deaths from breast, colon, and prostate cancer combined. In 2015, there will be an estimated 226,000 new cases of lung cancer diagnosed in the United States and over 160,000 individuals are expected to die from this disease (Cancer Facts and Figures 2015). Most patients will be diagnosed with locally advanced (stage III) or metastatic (stage IV) disease and the expected 5-year survival rate is only ~15% (Sozzi and Boeri 2014). Adenocarcinoma, the most common form of lung cancer, presents as a solitary pulmonary nodule which is easier to detect on CT than on a chest X-ray. Identification of patients at an early stage could potentially enable

oncologists to surgically remove the tumors.

Presently, there is no simple screening protocol for lung cancer that yields discriminatory results similar to those realized in breast (mammogram) and colon cancers (colonoscopy). The National Lung Screening Trial (NLST), initiated during 2002, established the potential utility of low dose CT (LDCT) screening to reduce lung cancer specific mortality in the high-risk population of current and former smokers (55–74 years of age, cigarette smokers with a history of at least 30 pack-years, and former smokers who quit smoking within the past 15 years). The data showed that there was a significant reduction (20%) in the death rates from lung cancer in participants who had LDCT compared to participants who had standard chest X-ray (National Lung Screening Trial Research Team, 2011); however, LDCT scans yield a high rate of false-positive results (National Lung Screening Trial

Research Team, 2011), (Wood et al., 2012), (Arenberg and Kazerooni 2012). In the NLST CT group, almost 40% of participants had at least 1 positive CT result during the study, but more than 96% of the positive test results in the CT group of the NLST were false-positive. Consequently, it may lead to unnecessary and costly biopsies or follow up Positron emission tomography-computed tomography (PET-CT) scans or follow up CT.

RECIST (Response Evaluation Criteria In Solid Tumors) criteria is being used to identify and follow nodules in lung cancer patients (Eisenhauer et al., 2009). However, it has limited capability to distinguish malignant nodules from benign lesions. In our study, we developed and tested a Support Vector Machine (SVM) based risk prediction model to investigate its performance in discriminating between malignant and benign nodules in asymptomatic high risk patients.

2 MATERIAL AND METHODS

2.1 CT Scan Image Analysis

CT images from 39 patients who participated in the NLST were obtained from National Cancer Institute (NCI), National Institute of Health. A trial-wide database is available for download at <https://biometry.nci.nih.gov/cdas/>, Cancer Data Access Systems (CDAS), NCI. The data set for each patient acquired at each year includes 100–300 slices of dicom images. An approval was obtained from Rutgers Internal Review Board to process the images.

Images were analyzed using software developed at the Center for Biomedical Imaging and Informatics, Rutgers Cancer Institute of New Jersey (<http://pleiad.umdnj.edu>). For each patient, a pulmonary nodule was first segmented on the Vitrea workstation (Vitrea 2; Vital Images, Plymouth, MN). Within the tumor region, texture analysis was performed using the Local Binary Pattern (LBP) method (Ojala et al., 1996). The local binary pattern of a single pixel is determined by its signal intensity relative to its neighbors (if a neighbor has signal intensity higher than that of the central pixel, then 1 is assigned; otherwise "0" is assigned). In this way, a binary sequence is generated for the pixel, indicating the relative variation in its signal intensity compared with its neighbors. In the binary sequence, the number of consecutive "1"s is counted as the LBP for the pixel, if all "1"s are consecutive; otherwise, the LBP is set as N+1 and not differentiated further.

With local binary pattern of each pixel obtained, the histogram of LBP is collected within the tumor region and normalized to eliminate the influence of tumor size. Although the local binary pattern can be measured at different scales (to capture the texture characteristics from fine to coarse), a single scale LBP was measured in this study due to the small size of some pulmonary nodules, where a small radius (1 pixel, 8 neighbors) was used. For each nodule, the volume of the nodule and its histogram of signal intensity were also calculated automatically.

Other features were specified by diagnostic radiologists in the Department of Radiology, Rutgers Robert Wood Johnson Medical School. Those features include the location of nodules (left, right; superior, middle, inferior), the margin of nodules (smooth, lobular, irregular, spiculated), the shape of nodules (round, oval, complex), the attenuation of nodules (soft tissue, ground glass, mixed, solid, calcium), the attachment of nodules (none, fissural, pleural), and whether the patient has emphysema. All the features specified or extracted from images were used as the input to statistical prediction model.

2.2 SVM based Risk Prediction Model

The prediction of malignancy of nodules was accomplished by establishing and using the SVM model. Support Vector Machine is a supervised learning algorithm (Cortes and Vapnik, 1995). The SVM classifier was established during the training procedure based on the clinical outcomes (malignant vs benign) and image features (extracted from CT images or specified by radiologists as described above). The optimal decision boundary was determined by maximizing the distance in features between two different classes. After a SVM prediction model was established, the prediction of tumor progression of a new patient could be automatically made based on his own image features. The prediction was compared with the clinical outcome (truth) for evaluation of accuracy, sensitivity, and specificity. Due to the limited sample size, we adopted leave-one-out approach to build the prediction model.

In the SVM classifier developed for this study, soft margin was used to allow for mislabeled samples, where training errors were incorporated into the cost function, and optimization became a tradeoff between a large margin and a small error penalty controlled by a parameter C. By using a nonlinear kernel, the SVM classifier permitted nonlinear decision boundary that fits data more

closely. When Gaussian Radial Basis function was used (as one of the most popular kernels), a parameter sigma determines how smoothly input features varied. The choice of parameters (C for soft margin and sigma for GRB) was determined by cross validation – the parameters with the best cross validation accuracy were selected during the training procedure and would be used for future predictions during the test procedure.

3 RESULTS

CT images obtained from 39 patients were analyzed in the present study. Pulmonary nodules were first segmented by diagnostic radiologists. Then texture features were automatically calculated using the Local Binary Pattern method, and 10D local binary histograms were generated, as shown in Figure 1.

Values were assigned for other imaging features (including tumor location, attachment, shape, attenuation, margin, and emphysema) depending on its possibility of malignancy, as shown in Table 1.

The SVM prediction model was used with RBF (radius basis function) kernel and soft margin. The prediction result is shown as follows:

Accuracy= 0.74, sensitivity = 0.85, specificity = 0.61.




Figure 1: Tumor segmentation and texture feature extraction.

Table 1: Image features specified by radiologists.

Location	Right Upper Lobe	1.0
	Right Middle Lobe	1.5
	Right Lower Lobe	2.0
	Left Lower Lobe	1.1
	Left Upper Lobe	2.1
Attachment	None	0
	Fissure	1
	Pleural	2
Shape	Oval	1
	Round	2
	Complex	3
Attenuation	Soft Tissue	1
	Ground glass	2
	Mixed	3
	Solid Density	4
Margins	Smooth	1
	Lobulated	2
	Irregular	3
Calcification	None	0
	Central	1
	Diffuse	2
Emphasyma	None	0
	Yes	1

4 DISCUSSION

Several lung cancer risk models have been established during the past ten years (Tammemagi, 2015). Risk factors were used to predict the probability that a person was likely to develop lung cancer (Bach et al., 2003), (Spitz et al., 2007), (Cassidy et al., 2008). More recently, radiology image features were incorporated to predict malignancy of pulmonary nodules (Sluimer et al., 2006) (Maldonado et al., 2013). In these studies, logistic regression model was widely used. However, in several recent clinical studies and simulations, SVM demonstrated better performance in various classification applications than the logistic regression model (Entezari-Maleki et al. 2009), (Wang and Huang 2011), (Salazar et al., 2012). In the present pilot study, we developed a SVM based model to discriminate malignant nodules from benign nodule.

While we recognize that the present study utilized a relatively small number of subjects, incorporation of CT scan data from more subjects could potentially increase the prediction accuracy of our present standalone model. In addition, we hypothesize that the incorporation of molecular biomarkers with the CT scan image data for both risk assessment and early diagnosis will further improve the diagnostic accuracy of LDCT (Rutman

and Kuo 2009), (Zander et al., 2011), (Gevaert et al., 2012), (Tammemagi, et al., 2013). There are a few reports on the integration of genomic data with CT scan image data (Showe et al., 2009) however, there is no commercial test available using the integrated approach to discriminate nodules in lung cancer. Further studies are in progress to analyze CT scan images and genomic data collected from high risk individuals.

ACKNOWLEDGEMENTS

This research was funded, in part, by grants from the National Institute of Health through contract 5R01CA161375-03 from the National Cancer Institute; and contract 5R01LM009239-06 from the National Library of Medicine (D.F.).

COMPETING INTEREST

E.Z. holds position and shares in OncoPath Genomics, Inc.

REFERENCES

- American Cancer Society. (2015) Cancer Facts and Figures. <http://www.cancer.org/research/cancerfacts/statistics/cancerfactsfigures2015/> Accessed on 10/10/2015.
- Arenberg, D., and Kazerooni, E.A., (2012). Setting up a lung cancer screening program. *Journal of the National Comprehensive Cancer Network*, 10(2):277–285.
- Bach, P.B., Kattan, M.W., Thornquist, M.D., Kris, M.G., Tate, R.C., Barnett, M.J., Hsieh, L.J., and Begg, C.B. (2003). Variations in lung cancer risk among smokers. *Journal of the National Cancer Institute*, 95(6): 470–478.
- Cassidy, A., Myles, J.P., Van-Tongeren, M., Page, R.D., Liloglou, T., Duffy, S.W. and Field, J.K. (2008). The LLP risk model: an individual risk prediction model for lung cancer. *British Journal of Cancer*, 98(2):270–276.
- Cortes, C., and Vapnik, V., (1995). Support-vector networks. *Machine Learning*, 20:273-297.
- Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). *European Journal of Cancer*, 45:228-247.
- Entezari-Maleki, R., Rezaei, A., and Minaei-Bidgoli, B., (2009). Comparison of Classification Methods Based on the Type of Attributes and Sample Size. *Journal of Convergence Information Technology*, 4(3):94-102.
- Gevaert, O., Xu, J., Hoang, C.D., Leung, A.N., Xu, Y., Quon, A., Rubin, D.L., Napel, S., and Plevritis, S.K. (2012). Non-Small Cell Lung Cancer: Identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-Methods and preliminary results. *Radiology*, 264(2):387-396.
- Maldonado, F., Boland, J.M., Raghunath, S., et al. (2013). Non-invasive Characterization of the Histopathologic Features of Pulmonary Nodules of the Lung Adenocarcinoma Spectrum using Computer Aided Nodule Assessment and Risk Yield (CANARY) – a Pilot Study. *Journal of Thoracic Oncology*, 8(4): 452-460.
- National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. *New England Journal of Medicine*, 365(5):395-409.
- Ojala, T., Pietikainen, M., and Harwood, D., (1996). A comparative study of texture measures with classification based on featured distributions. *Pattern recognition*, 29(1):51-59.
- Rutman, A.M., and Kuo, M.D., (2009). Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. *European Journal of Radiology*, 70(2):232–241.
- Salazar, D.A., Velez, J.I., and Salazar, J.C., (2012). Comparison between SVM and Logistic Regression: Which One is better to Discriminate? *Revista Colombiana de Estadística Número especial en Bioestadística*, 35:223-237.
- Showe, M.K., Vachani, A., Kossenkov, A.V., et al. (2009). Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non-Small-Cell Lung Cancer from Patients with Non-Malignant Lung Disease. *Cancer Research*, 69(24):9202–9210.
- Sluimer, I., Schilham, A., Prokop, M., and Van-Ginneken, B. (2006). Computer Analysis of Computed Tomography Scans of the Lung: A Survey. *IEEE Transactions on Medical Imaging*, 25(4):385-405.
- Sozzi, G., and Boeri, M., (2014). Potential biomarkers for lung cancer screening. *Transl. Lung Cancer Research*, 3(3):139-148.
- Spitz, M.R., Hong, W.K., Amos, C.I., Wu, X., Schabath, M.B., Dong, Q., Shete, S. and Etzel, C.J. (2007). A risk model for prediction of lung cancer. *Journal of the National Cancer Institute*, 99(2):715–726.
- Tammemagi, M.C., Katki, H.A., Hocking, W.G., et al. (2013). Selection criteria for lung cancer screening. *New England Journal of Medicine*, 368(8):728–736.
- Tammemagi, M.C., (2015). Application of Risk Prediction Models to Lung Cancer Screening: a review. *Journal of Thoracic Imaging*, 30(2):88–100.
- Wang, H., and Huang, G., (2011). Application of support vector machine in cancer diagnosis. *Medical Oncology*, 28(1):613-618.
- Wood, D.E., Eapen, G.A., Ettinger, D.S., et al. (2012). Lung cancer screening. *Journal of the National Comprehensive Cancer Network*, 10(2):240–265.
- Zander, T., Hofmann, A., Staratschek-Jox, A., et al.

(2011). Blood-Based Gene Expression Signatures in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, 17(10):3360-3367.

